Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV
Elahe Taki, Faezeh Soleimani, Arezoo Asadi, et al.
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 8, pp. 1135-1147
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

A review: FDA-approved fluorine-containing small molecules from 2015 to 2022
Negar Sheikhi, Maryam Bahraminejad, Mina Saeedi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115758-115758
Closed Access | Times Cited: 42
Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection
Mohammad Ullah Nayan, Brady Sillman, Mahmudul Hasan, et al.
Advanced Drug Delivery Reviews (2023) Vol. 200, pp. 115009-115009
Open Access | Times Cited: 23
Nanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems
Benjamin Rossier, Olivier Jordan, Éric Allémann, et al.
Drug Delivery and Translational Research (2024) Vol. 14, Iss. 12, pp. 3438-3451
Open Access | Times Cited: 12
Solubilization techniques used for poorly water-soluble drugs
Bing Xie, Yaping Liu, Xiaotong Li, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 11, pp. 4683-4716
Open Access | Times Cited: 10
Development of a Cr2AlC MAX phase/g-C3N4 composite-based electrochemical sensor for accurate cabotegravir determination in pharmaceutical and biological samples
Wiem Bouali, A. Genç, Nevin Erk, et al.
Microchimica Acta (2024) Vol. 191, Iss. 3
Closed Access | Times Cited: 8
Fighting nature with nature: antiviral compounds that target retroviruses
Zhen Yun Siew, Elishea Asudas, Chia Ting Khoo, et al.
Archives of Microbiology (2024) Vol. 206, Iss. 3
Closed Access | Times Cited: 6
Preferences for longer acting pre-exposure prophylaxis in transgender and gender expansive texans: centering gender affirming hormone therapy
Julie A. Zuñiga, Julie E. Mellin, Gabrielle Benitez, et al.
AIDS Care (2025), pp. 1-10
Open Access
Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir
Mohsen Heidary, Saeedeh Shariati, Shima Nourigheimasi, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
State of the ART (antiretroviral therapy): Long-acting HIV-1 therapeutics
S Ravichandran, William M. McFadden, Alexa A. Snyder, et al.
Global Health & Medicine (2024)
Closed Access | Times Cited: 3
Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency
Christin Rogers Marks, Christine M. Durand, Mary G. Bowring, et al.
Transplant Infectious Disease (2024) Vol. 26, Iss. 4
Closed Access | Times Cited: 2
Low Uptake of Long-Acting Injectables in the First 2.5 Years Following Approval Among a Cohort of People Living With HIV
Priyanka Manghani, Anne K. Monroe, Amanda D. Castel, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 5
Open Access | Times Cited: 2
Discovery of 2,4,6-trisubstituted Pyrimidine Derivatives as Novel Potent HIV-1 NNRTIs by Exploiting the Tolerant Region II of the NNIBP
Zhenzhen Zhou, Yanying Sun, Yanyang Qin, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116708-116708
Closed Access | Times Cited: 2
New designs for HIV-1 integrase inhibitors: a patent review (2018-present)
Yoshiyuki Taoda, Shuichi Sugiyama, Takahiro Seki
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 1, pp. 51-66
Closed Access | Times Cited: 6
Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Murugesan Vanangamudi, Palaniappan Senthilkumar, M. K. Kathiravan, et al.
Viruses (2023) Vol. 15, Iss. 10, pp. 1992-1992
Open Access | Times Cited: 5
Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals
Maria Vittoria Cossu, Dario Cattaneo, Davide Moschese, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 5, pp. 1126-1132
Closed Access | Times Cited: 1
New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs
Maria Marra, Alessia Catalano, Maria Stefania Sinicropi, et al.
Viruses (2024) Vol. 16, Iss. 9, pp. 1484-1484
Open Access | Times Cited: 1
Human immunodeficiency virus infection challenges: Current therapeutic limitations and strategies for improved management through long‐acting injectable formulation
Tanushree, Aman Sharma, M. Lamba, et al.
Reviews in Medical Virology (2024) Vol. 34, Iss. 4
Closed Access | Times Cited: 1
A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine
Diego Ripamonti, Stefano Rusconi, Maurizio Zazzi
AIDS (2023) Vol. 38, Iss. 2, pp. 263-265
Closed Access | Times Cited: 2
HIV Cure: How Far We Have Come?
Shesh Prakash Maurya, Abhishek Shrivastav, Vivek Singh Rawat, et al.
Indian Journal of Microbiology (2024)
Closed Access
Intolerancia a vía oral: nuevo escenario para la terapia antirretroviral parenteral
Sergio Ferra Murcia, Ana Belén Lozano Serrano, Marta Segura Díaz, et al.
Enfermedades Infecciosas y Microbiología Clínica (2024) Vol. 42, Iss. 9, pp. 535-536
Closed Access
Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022
Zhaoquan Wang, He Jiang, Xianwu Pang, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 10, pp. 2575-2585
Closed Access
Oral intolerance: new scenario for parenteral antiretroviral therapy
Sergio Ferra Murcia, Ana Belén Lozano Serrano, Marta Segura Díaz, et al.
Enfermedades infecciosas y microbiologia clinica (English ed ) (2024) Vol. 42, Iss. 9, pp. 535-536
Closed Access
Doravirine (Pifeltro): A Third‐Generation Non‐Nucleoside Reverse Transcriptase Inhibitor as a Treatment of HIV ‐1 Infection

(2024), pp. 29-52
Closed Access
Nanoparticle-Based Drug Delivery for Infectious Diseases
Ashrafi Sultana, Mohammad Ullah Nayan
(2024), pp. 349-378
Closed Access
Barriers and facilitators to equitable implementation of long-acting ART for adolescents and youth with HIV in low- and middle-income settings
Nadia A. Sam‐Agudu, Chibueze Adirieje, Allison L. Agwu, et al.
Pan African Medical Journal (2024) Vol. 49
Open Access
Page 1 - Next Page

Scroll to top